A Case of Bilateral Congenital Dacryocystocele Infected with Serratia marcescens

References

1. 1. Nesi FA, Lishman RD, Levine MR. Ophthalmic plastic and reconstructive surgery. 2nd ed. Congenital lacrimal disorders. St.Louis: Mosby-Year Book, Inc.; 1998. 2. Vagge A, Ferro Desideri L, Nucci P, Serafino M, Giannaccare G, Lembo A, Traverso CE.Congenital Nasolacrimal Duct Obstruction (CNLDO):A Review. Diseases. 2018 Oct 22;6(4). 3. Becker BB. The treatment of congenital dacryocystocele. Am J Ophthalmol 2006;142:835-838. 4. Wong RK, VanderVeen DK. Presentation and management of congenital dacryocystocele. Pediatrics 2008;122:e1108-e1112. 5. Al-Faky YL, Naeem T, Al-Sobaie N, Al-Huthail R, Al-Odan H, Osman EA, et al. Value of microbiology study in congenital nasolacrimal duct obstruction. Saudi J Ophthalmol 2012;26: 223-8. 6. Ewete T, Alabi AS.Serratia marcescens Lacrimal Canaliculitis. Ophthalmology Research: An International Journal 6(2): 1-4, 2016. 7. Parment PA. The role of Serratia marcescens in soft contact lens associated ocular infections. Acta Ophthalmol. Scand. 1997: 75: 67-71. 8. MacEwen CJ, Young JD. Epiphora during the first year of life. Eye 1991, 5, 596–600. 9. Cavazza S, Laffi GL, Lodi L, Tassinari G, Dall'Olio.Acta Otorhinolaryngol Ital. 2008 Dec;28(6):298-301. Congenital dacryocystocele: diagnosis and treatment. Congenital Dacryocystocele: diagnosis and treatment. Acta Otorhinolaryngol Ital 2008;28:298-301.

Cited by

0 — Crossref — cited-by count (retrieved 2 Oct 2026, source)

Citation counts are shown with their source and retrieval date. They are not an Impact Factor or any journal-level metric.